Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuCorVac-19 vs ChAdOx1 in Healthy Adults
NCT05572879Phase 3Completed
- Sponsor
- EuBiologics
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Targeted Liposomes, Recombinant Protein Vaccines, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 3 trial of eucorvac-19 in coronavirus disease 2019 (COVID-19), sponsored by EuBiologics. Started Oct 2022; status: completed.
02
Drugs
eucorvac-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05572879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05572879.